Please assess the completion status of the following clinical trial:

Trial Title: Durvalumab in HIV-1 Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent~2. Age \> 18 years at time of study entry.~3. Eastern Cooperative Oncology Group (ECOG) 0-2~4. Life expectancy of \> 16 weeks~5. Adequate normal organ and marrow function.~6. Female subjects must either be of non-reproductive potential~7. Subject is willing and able to comply with the protocol~8. Subjects with histologically or cytologically advanced/metatasic-documented lung cancer, head and neck cancer, cervical cancer, melanoma, anal cancer, pancreatic cancer, gastrio-esophageal cancer, triple negative breast cancer, bladder or renal cancer, Cholangiocarcinoma, Kaposi sarcoma, lymphomas, ovarian cancer or Merkel cell carcinoma or any other tumor type in which anti PD-L1 antibodies have desmonstrated antitumoral activity, refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists or who refuse the standard treatment.~9. Subjects may be included irrespectively of number of previous lines of treatment for advanced disease.~10. Prior palliative radiotherapy must have been completed at least 2 weeks prior to start the study treatment (subjects may receive localized palliative radiotherapy while receiving study drug).~11. Documented HIV-1 infection.~12. Undetectable viral load in the last analysis.~13. Subjects with brain metastases are eligible if they are asymptomatic, are treated or are neurological stable for at least 2 weeks without the use of steroids or on stable or decreasing dose of\<10mb daily prednisone or equivalent.~14. Subjects must be following an antiretroviral therapy at the moment of the inclusion.~Exclusion Criteria:~1. Involvement in the planning and/or conduct of the study. Previous enrollment in the present study.~2. Participation in another clinical study within last 4 weeks.~3. Other untreated coexisting HIV related malignancies.~4. Any previous treatment with a PD1, PD-L1 or PD-L2 inhibitor, including durvalumab.~5. Receipt of the last dose of anti-cancer therapy within 28 days prior to the first dose of study drug.~6. Mean QT interval corrected for heart rate (QTc) ≥470 ms~7. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab,~8. Any unresolved toxicity (CTCAE grade 2) from previous anti-cancer therapy.~9. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1.~10. Active or prior documented autoimmune disease within the past 2 years~11. Any syndrome that requires systemic corticosteroid/immunosuppressive medications~12. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).~13. History of primary immunodeficiency.~14. History of allogeneic organ transplant.~15. History of hypersensitivity to durvalumab or any excipient.~16. Uncontrolled intercurrent illness~17. Known history of active tuberculosis.~18. Any serious or uncontrolled medical disorder or active infection non HIV, that would impair the ability of the subject to receive the treatment of protocol therapy under treating physician criteria.~19. Subjects with previous malignances, are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.~20. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab.~21. Female subjects who are pregnant, breast-feeding, male, or female patients of reproductive potential who are not employing an effective method of birth control.~22. Symptomatic or uncontrolled brain metastases~23. Subjects with uncontrolled seizures.~24. Patients with tumoral disease in the head and neck region, such as peritracheal or periesophageal lymph node involvement,~25. Patients with neuroendocrine tumors of pulmonary origin or pulmonary metastases with evidence of active bleeding~26. Patients with digestive bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete